

Transforming Relapsed/ Refractory MCL

Exploring New Options for Your Patients

Tuesday 13 June 2023 • 11:30 – 13:00 CEST
International Conference on Malignant Lymphoma
Palazzo dei Congressi, Lugano, Switzerland
First Floor, Room B2

Agenda

- The Evolving Landscape of Treatment Options for R/R MCL
- Build Your Own Case Studies LIVE
 - **Part 1:** Differentiate between 2nd and 3rd line therapy for patients with or without prior exposure to BTKi Therapy in R/R MCL
 - **Part 2:** Sequencing considerations
 - **Part 3:** Address safety concerns, including monitoring for and mitigating adverse reactions
- The Importance of Collaboration Between Providers and Patients
- Faculty/Learner Exchange



Mats Jerkeman, MD, PhD
Lund, Sweden



Prof. Dr. med. Christiane Pott
Kiel, Germany



Carlo Visco, MD
Verona, Italy

This activity is supported by an educational grant from Lilly.

Approved for 1.5 AMA PRA Category 1.5 Credit™, 1.5 CME-CPD credit by European Board of Accreditation in Hematology (EBAH) and 2.0 SGH credit by Swiss Society of Hematology (SSH)

17-ICML Satellite Symposium.

This activity is provided by
Medical Learning Institute, Inc.

